VECURONIUM BROMIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Vecuronium Bromide, and when can generic versions of Vecuronium Bromide launch?
Vecuronium Bromide is a drug marketed by Eugia Pharma, Gland, Hikma, Hospira, Meitheal, Mylan Labs Ltd, Sagent Pharms Inc, Sun Pharm, and Watson Labs. and is included in twelve NDAs.
The generic ingredient in VECURONIUM BROMIDE is vecuronium bromide. There are six drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the vecuronium bromide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Vecuronium Bromide
A generic version of VECURONIUM BROMIDE was approved as vecuronium bromide by MEITHEAL on August 25th, 1999.
Summary for VECURONIUM BROMIDE
US Patents: | 0 |
Applicants: | 9 |
NDAs: | 12 |
Finished Product Suppliers / Packagers: | 9 |
Raw Ingredient (Bulk) Api Vendors: | 84 |
Clinical Trials: | 12 |
Patent Applications: | 1,814 |
Formulation / Manufacturing: | see details |
DailyMed Link: | VECURONIUM BROMIDE at DailyMed |
Recent Clinical Trials for VECURONIUM BROMIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University | Phase 4 |
Guangdong Provincial People's Hospital | Phase 4 |
Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 4 |
Pharmacology for VECURONIUM BROMIDE
Drug Class | Nondepolarizing Neuromuscular Blocker |
Physiological Effect | Neuromuscular Nondepolarizing Blockade |